RTP Mobile Logo

Thursday, April 30, 2020, San Antonio, Texas, 6:00 AM – 7:30 AM

Oncology Grand Rounds: Nurse and Physician Investigators Discuss New Agents, Novel Therapies and Actual Cases from PracticeA CNE (NCPD) Symposia Series Associated with the ONS 45th Annual Congress

PARP Inhibition in the Management of Common Cancers

Update regarding COVID-19

The ONS Board of Directors has made the difficult decision to cancel the 45th Annual ONS Congress scheduled to take place in San Antonio, April 29-May 3, 2020. ONS is exploring alternatives for delivering the educational sessions. For up-to-date information on this program, please sign up for our email alerts.

Last updated 4/8/2020

Event Details

Location
Grand Hyatt San Antonio
600 East Market Street
San Antonio, TX 78205

Hotel Phone: (210) 224-1234

Meeting Room
Texas Ballroom ABC (Fourth Floor)
Schedule
5:30 AM – 6:00 AM
Registration and Breakfast Buffet

6:00 AM – 7:30 AM
Educational Program
 
There is no registration fee for this event. Preregistration is highly recommended as seating and meal service are limited.

Faculty
Emmanuel S Antonarakis, MD
Professor of Oncology and Urology
Johns Hopkins University
The Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Kathleen Moore, MD
The Virginia Kerley Cade Endowed Chair in
Cancer Development
Associate Director, Clinical Research
Director, Oklahoma TSET Phase I Program
Stephenson Cancer Center
Associate Professor, Section of Gynecologic Oncology
Director, Gynecologic Oncology Fellowship
Department of Obstetrics and Gynecology
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma

Joyce O’Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Director, Breast Cancer Research Program
Texas Oncology
US Oncology
Dallas, Texas

Michael J Pishvaian, MD, PhD
Associate Professor
Department of Gastrointestinal Medical Oncology
Co-Director for Clinical Research
Sheikh Ahmed Bin Zayed Al Nahyan Center for Pancreatic Cancer Research
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Moderator
Neil Love, MD
Research To Practice
Miami, Florida
 
Meeting space has been assigned to provide a satellite symposium supported by AstraZeneca Pharmaceuticals LP and Merck during the Oncology Nursing Society’s (ONS) 45th Annual Congress, April 29 to May 3, 2020 in San Antonio, Texas. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.

Agenda

Topics for Discussion

  • Module 1: Ovarian Cancer
  • Module 2: Breast Cancer
  • Module 3: Prostate Cancer
  • Module 4: Pancreatic Cancer
A detailed agenda will be made available by late March.

CE Information

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of cancer.

Learning Objectives and Goals
Upon completion of this activity, participants should be able to:

  • Comprehend how DNA damage repair pathway abnormalities can be exploited via PARP inhibi­tion to elicit therapeutic benefit for patients with various neoplasms, including ovarian cancer, breast cancer, pancreatic adenocarcinoma and prostate cancer.
  • Understand the correlation between BRCA1/2 mutations and the development of hereditary cancers, and counsel patients with these genetic abnormalities regarding their long-term outlook and therapeu­tic options.
  • Assess available and emerging clinical trial data with and FDA-approved indications for the various PARP inhibitors used for ovarian cancer, and develop strategies to identify patients for whom PARP inhibition might be appropriate.
  • Recognize the FDA-endorsed indications for the commercially available PARP inhibitors in the man­agement of metastatic breast cancer, and discern how these agents can be optimally employed in nonresearch patient care.
  • Advise individuals with metastatic pancreatic adenocarcinoma found to harbor a germline BRCA mutation about recently presented clinical trial findings documenting the efficacy of PARP inhibitor maintenance therapy after the completion of first-line platinum-based chemotherapy.
  • Describe the rationale for testing patients with metastatic prostate cancer for BRCA1/2 or other related mutations, and advise individuals found to harbor these genetic abnormalities about emerging Phase III data doc­umenting the efficacy of PARP inhibition for their disease.
  • Assess the pharmacologic, pharmacodynamic and pharmacokinetic similarities and differences among the commercially available and investigational PARP inhibitors to better understand the activity and toxicities associated with these agents.
Accreditation Statement
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by RTP.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

To obtain a certificate of completion and receive credit for this event, nurses must sign in at the registration desk upon arrival, attend the entire activity and return a completed Educational Assessment and Credit Form upon exiting the activity.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
This activity will be submitted to the ONCC for ILNA verification.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures
RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE (NCPD) activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

RTP CNE (NCPD) planning committee members, staff and reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Merck.

Location

Grand Hyatt San Antonio
600 East Market Street
San Antonio, TX 78205

Hotel Phone: (210) 224-1234

Meeting Room
Texas Ballroom ABC (Fourth Floor)

The Grand Hyatt San Antonio is conveniently located adjacent and connected to the Henry B Gonzalez Convention Center, where the ONS 45th Annual Congress is taking place.